Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study
ConclusionIn PREFERMS, fingolimod was associated with better treatment retention than iDMTs in African-American patients. Optimal outcomes in the management of multiple sclerosis depend on good persistence with treatment, and this is particularly important in patient populations at increased risk of a rapidly progressing disease course. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - July 20, 2018 Category: Neurology Source Type: research
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African–American patients: A subgroup analysis of a randomized phase 4 study
Conclusion: In PREFERMS, fingolimod was associated with better treatment retention than iDMTs in African–American patients. Optimal outcomes in the management of multiple sclerosis depend on good persistence with treatment, and this is particularly important in patient populations at increased risk of a rapidly progressing disease course.Trial Registration: NCT01623596.Funding: Novartis Pharmaceuticals Corporation. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - July 11, 2018 Category: Neurology Source Type: research
Neutralizing antibody production against Rebif ® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.
CONCLUSION: Receiving interferon beta-1a for >24 months is correlated with higher possibility of NAb production. The type of IFN-β used in the study had no significant impact on NAb positivity. In addition, both groups had comparable EDSS score changes, and NAb status of patients was correlated with their EDSS score.
PMID: 29990690 [PubMed - as supplied by publisher] (Source: International Immunopharmacology)
Source: International Immunopharmacology - July 7, 2018 Category: Allergy & Immunology Authors: Shokrollahi Barough M, Ashtari F, Sadat Akhavi M, Asghari N, Mosayebi G, Mirmohammadkhani M, Kokhaei N, Bahraminia F, Ajami A, Kokhaei P Tags: Int Immunopharmacol Source Type: research
In vitro and computational studies on the effects of ARE deletion and targeted mutations on the expression of interferon beta-1a in HEK293T cells.
Abstract
Interferon beta (IFNβ) is transiently expressed in response to viral infections and widely used to treat relapsing-remitting multiple sclerosis (MS). We introduced mutations in the IFNβ gene (in the 27th and 101st codons and in the Kozak sequence, and also deletion of 3' and 5' unstable, untranslated region, UTR) with the aim of increasing the expression of IFNβ. Computational analyses of mutant and wild-type RNAs and proteins of IFNβ by RNAfold, ASAView, HOPE and Ramachandran plot, and iStable web servers showed that the mutations could decrease RNA stability, protein solvent accessibility, a...
Source: Applied Microbiology and Biotechnology - June 21, 2018 Category: Microbiology Authors: Norouzi R, Hojati Z, Dehbashi M Tags: Appl Microbiol Biotechnol Source Type: research
Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study
This study aimed to assess the effect of active T2 and T1 gadolinium-enhancing (Gd... (Source: BMC Neurology)
Source: BMC Neurology - May 11, 2018 Category: Neurology Authors: Anthony Traboulsee, David K. B. Li, Mark Cascione, Juanzhi Fang, Fernando Dangond and Aaron Miller Tags: Research article Source Type: research
